Effects of treatment with a 5‐HT4receptor antagonist in heart failure
- 29 January 2007
- journal article
- Published by Wiley in British Journal of Pharmacology
- Vol. 150 (2) , 143-152
Abstract
Background and purpose: Positive inotropic responses (PIR) to 5‐hydroxytryptamine (5‐HT) are induced in the left ventricle (LV) in rats with congestive heart failure (CHF); this is associated with upregulation of the Gs‐coupled 5‐HT4receptor. We investigated whether chronic 5‐HT4receptor blockade improved cardiac function in CHF rats.Experimental approach: Rats were given either the 5‐HT4antagonist SB207266 (0.5 mg kg−124h−1; MIint) or placebo (MIpl) through mini‐osmotic pumps for 6 weeks subsequent to induction of post‐infarction CHF.In vivocardiac function andex vivoresponses to isoprenaline or 5‐HT were evaluated using echocardiography and isolated LV papillary muscles, respectively. mRNA levels were investigated using real‐time quantitative RT‐PCR.Key results: LV diastolic function improved, with 4.6% lower LV diastolic diameter and 24.2% lower mitral flow deceleration in MIintcompared to MIpl. SB207266 reduced LV systolic diameter by 6.1%, heart weight by 10.2% and lung weight by 13.1%. The changes in posterior wall thickening and shortening velocity, cardiac output, LV systolic pressure and (dP/dt)max, parameters of LV systolic function, did not reach statistical significance. The PIR to isoprenaline (10 μM) increased by 36% and the response to 5‐HT (10 μM) decreased by 57% in MIintcompared to MIpl. mRNA levels for ANP, 5‐HT4(b)and 5‐HT2Areceptors, MHCβ, and the MHCβ/MHCα‐ratio were not significantly changed in MIintcompared to MIpl.Conclusions and implications: Treatment with SB207266 to some extent improvedin vivocardiac function andex vivomyocardial function, suggesting a possible beneficial effect of treatment with a 5‐HT4receptor antagonist in CHF.British Journal of Pharmacology(2007)150, 143–152. doi:10.1038/sj.bjp.0706966Keywords
This publication has 53 references indexed in Scilit:
- Effects of spironolactone and eprosartan on cardiac remodeling and angiotensin-converting enzyme isoforms in rats with experimental heart failureAmerican Journal of Physiology-Heart and Circulatory Physiology, 2005
- Carvedilol therapy is associated with a sustained decline in brain natriuretic peptide levels in patients with congestive heart failureAmerican Heart Journal, 2005
- Modification of myosin protein and gene expression in failing hearts due to myocardial infarction by enalapril or losartanBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2004
- Changes in myocardial gene expression associated with β-blocker therapy in patients with chronic heart failureJournal of Cardiac Failure, 2003
- Increased contribution of α1‐ vs. β‐adrenoceptor‐mediated inotropic response in rats with congestive heart failureActa Physiologica Scandinavica, 2003
- 5-Hydroxytryptamine 4(a) Receptor Is Coupled to the Gα Subunit of Heterotrimeric G13 ProteinJournal of Biological Chemistry, 2002
- Selective β1-Blockade Improves Cardiac Bioenergetics and Function and Decreases Neuroendocrine Activation in Rats during Early Postinfarct RemodelingBiochemical and Biophysical Research Communications, 2001
- Receptor mechanisms involved in the 5‐HT‐induced inotropic action in the rat isolated atriumBritish Journal of Pharmacology, 1998
- Downregulation of adenylylcyclase types V and VI mRNA levels in pacing-induced heart failure in dogs.Journal of Clinical Investigation, 1994
- Decreased Catecholamine Sensitivity and β-Adrenergic-Receptor Density in Failing Human HeartsNew England Journal of Medicine, 1982